Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
COMPASS Pathways (CMPS)
NASDAQ:CMPS
COMPASS Pathways (CMPS) Stock Price & Analysis
1,115 Followers
CMPS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$5.01 - $12.75
Previous Close$7.86
Volume623.17K
Average Volume (3M)643.72K
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)$143.21M
Total Debt (Recent Filing)$1.93M
Price to Earnings (P/E)N/A
Beta1.44
Next Earnings
Aug 01, 2024EPS Estimate
-$0.53Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding45,621,680
10 Day Avg. Volume408,232
30 Day Avg. Volume643,720
Standard Deviation0.22
R-Squared0.31
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)2.09
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-4.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$45.00Price Target Upside472.52% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
COMPASS Pathways News
Bulls Say, Bears Say
Bulls Say
Drug Development ProgressCOMP360 is advancing in clinical trials with top-line data expected, potentially leading to a groundbreaking new depression treatment.
Financial OutlookWith analysts reiterating a strong Buy rating and a high price target, COMP360's success could translate into significant revenue growth.
Market PotentialCOMP360 shows promise in multiple psychiatric indications, indicating a broad market potential and a boost in shareholder value upon successful approval.
Bears Say
Clinical Trial DelaysCOMP-005 study has been delayed due to record-keeping procedures in the US increasing the difficulty of confirming a TRD diagnosis.
Financial PerformanceOperating expenses of $38.4mn came in higher than the expected $17.3mn mainly due to unpredictable timing on an R&D credit.
Management ChangesGeorge Goldsmith and Dr. Katya Malievskaya resigned from their board seats.
---
Ownership Overview
36.13% Insiders
0.26% Mutual Funds
11.80% Other Institutional Investors
51.80% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CMPS FAQ
What was COMPASS Pathways’s price range in the past 12 months?
COMPASS Pathways lowest stock price was $5.01 and its highest was $12.75 in the past 12 months.
What is COMPASS Pathways’s market cap?
Currently, no data Available
When is COMPASS Pathways’s upcoming earnings report date?
COMPASS Pathways’s upcoming earnings report date is Aug 01, 2024 which is in 82 days.
How were COMPASS Pathways’s earnings last quarter?
COMPASS Pathways released its earnings results on May 08, 2024. The company reported -$0.55 earnings per share for the quarter, missing the consensus estimate of -$0.482 by -$0.068.
Is COMPASS Pathways overvalued?
According to Wall Street analysts COMPASS Pathways’s price is currently Undervalued.
Does COMPASS Pathways pay dividends?
COMPASS Pathways does not currently pay dividends.
What is COMPASS Pathways’s EPS estimate?
COMPASS Pathways’s EPS estimate is -$0.53.
How many shares outstanding does COMPASS Pathways have?
COMPASS Pathways has 68,380,860 shares outstanding.
What happened to COMPASS Pathways’s price movement after its last earnings report?
COMPASS Pathways reported an EPS of -$0.55 in its last earnings report, missing expectations of -$0.482. Following the earnings report the stock price went down -0.468%.
Which hedge fund is a major shareholder of COMPASS Pathways?
Among the largest hedge funds holding COMPASS Pathways’s share is ARK Investment Management LLC. It holds COMPASS Pathways’s shares valued at 23M.
---
COMPASS Pathways Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$45.00 (472.52% Upside)
$45.00 (472.52% Upside)
Blogger Sentiment
Bullish
CMPS Sentiment 83%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 266.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 2.4%
Last 30 Days ▼ 2.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-8.49%
12-Months-Change
Fundamentals
Return on Equity
-61.60%
Trailing 12-Months
Asset Growth
78.29%
Trailing 12-Months
Company Description
COMPASS Pathways
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies, and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.
---
CMPS Earnings Call
Q1 2024
0:00 / 0:00
---
CMPS Stock 12 Month Forecast
Average Price Target
$45.00
▲(472.52% Upside)
Technical Analysis
Best Analysts Covering CMPS
1 Year
1 Year Success Rate
3/8 ratings generated profit
1 Year Average Return
-8.75%
reiterated a buy rating 2 months ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 37.50% of your transactions generating a profit, with an average return of -8.75% per trade.
---